Supplementary Figure S3 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial
Karama Asleh(University of British Columbia), Saranya Chumsri(Jacksonville College), Henrik Lindman(Uppsala University), Torsten O. Nielsen(University of British Columbia), Amy Sullivan, E. Aubrey Thompson, Heather Ann Brauer(Gates Foundation), Heikki Joensuu(Orion Corporation (Finland)), Susanna Lauttia(University of Helsinki)
Cited by 0
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k